Merck & Co., Inc. Presents New Pharmacokinetic Data on ISENTRESS® (raltegravir) at 14th European AIDS Conference
Published: Oct 16, 2013
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is presenting pharmacokinetic data this week on investigational formulations of a once daily (QD) dose of ISENTRESS at the 14th European AIDS Conference (EACS), sponsored by the European AIDS Clinical Society. The meeting is currently taking place in Brussels, Belgium, Oct. 16-19, 2013.
Help employers find you! Check out all the jobs and post your resume.